Shamburg News · 8-K filed Oct 26, 2026, 8:13 AM EDT

Aptevo Reports Ten Frontline AML Patients Advanced to Stem Cell Transplant on Mipletamig Regimen

APVO · Aptevo Therapeutics Inc.

  • Other event
  • Materiality: medium

On October 26, 2026, Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia have advanced to allogeneic stem cell transplant after treatment with mipletamig combined with venetoclax and azacitidine. The filing states this represents ten of 47 (21%) evaluable frontline patients, nine from the ongoing Phase 1b RAINIER trial and one from a previously completed dose expansion trial. The company also said RAINIER dose optimization is expected to conclude by year-end 2026, with regulatory discussions anticipated in the first half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-431079.

Written from the filing by Shamburg Markets. Figures are as reported by the company.